Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy.
Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival benefits versus their comparators in randomized controlled trials, and other agents are showing promising results. A future in which metastatic castrate-resistant prostate cancer can be managed as a 'chronic disease' looks tantalizingly close. The challenge for clinicians will be to use these treatments rationally, in a way that optimizes each individual patient's chances of prolonged survival.
Birtle A. Are you the author?
Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Fulwood, Preston, Lancashire, PR2 9HT, UK.
Reference: Expert Rev Anticancer Ther. 2013 Jan;13(1):89-99.